2025-09-15 - Analysis Report
Okay, here's a report analyzing Albemarle Corp (ALB), incorporating the provided data.

**Report: Albemarle Corp (ALB) Analysis**

**Company Overview:** Albemarle Corp (ALB) is a specialty chemicals company with leading positions in lithium, bromine specialties, and catalysts.

**1. Performance vs. S&P 500 (VOO)**

*   **Accumulated Return (ALB):** 21.78%
*   **Accumulated Return (VOO):** 104.48%
*   **Absolute Divergence (ALB - VOO):** -92.6%
*   **Relative Divergence:** 1.6 (on a scale where min is -97.5 and max is 215.1)

**Analysis:** ALB has significantly underperformed the S&P 500 (VOO) over the period covered. The relative divergence indicates ALB is positioned near the lower end of its historical divergence range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta   | Cap(B) |
|------------|--------|--------|--------|--------|--------|
| 2015-2017  | 99.0%  | 8.1%   | 70.0%  | 0.0    | 15.1   |
| 2016-2018  | 13.0%  | 58.0%  | -5.0%  | 0.0    | 9.1    |
| 2017-2019  | -44.0% | 58.0%  | -74.0% | -0.0   | 8.6    |
| 2018-2020  | 101.0% | 62.9%  | 81.0%  | 0.6    | 17.4   |
| 2019-2021  | 268.0% | 62.9%  | 220.0% | 0.6    | 27.5   |
| 2020-2022  | 239.0% | 75.6%  | 237.0% | 0.8    | 25.5   |
| 2021-2023  | -53.0% | 77.5%  | -71.0% | 0.6    | 17.0   |
| 2022-2024  | -200.0%| 77.5%  | -225.0%| 0.7    | 10.1   |
| 2023-2025  | -326.0%| 77.5%  | -383.0%| 2.9    | 8.9    |

**Analysis:**

*   **CAGR:**  Volatile, with periods of extremely high growth (2019-2022) followed by significant declines recently.
*   **MDD:** Maximum Drawdown is high, indicating substantial risk. Especially concerning is the consistent 77.5% MDD for the most recent periods.
*   **Alpha:**  Mixed performance.  While some periods showed strong outperformance (positive Alpha), recent years have exhibited significant underperformance (negative Alpha).  The trend is strongly negative.
*   **Beta:**  Beta values have been relatively low for extended periods, but have risen sharply in the last period, suggesting a change in correlation with the market.
*   **Cap:** Market Cap declined sharply

**2. Recent Stock Price Movement**

*   **Current Price:** $75.98
*   **Previous Close:** $74.645
*   **Change:** 1.79
*   **5-day Moving Average:** $75.786
*   **20-day Moving Average:** $80.2325
*   **60-day Moving Average:** $73.9172

**Analysis:** The current price is above the 5-day and 60-day moving averages but below the 20-day moving average. This suggests a potential short-term upward trend, but longer-term trend is uncertain. The price increase compared to the previous close indicates a positive short-term movement.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 41.18 (Approaching oversold territory)
*   **PPO:** -1.586
*   **Hybrid Signal:** cash_69%_Sell 0.8% of holdings (5 shares - Caution - MRI:0.33) (Cash Ratio: 69% on 2025-09-05)
*   **20-day Relative Divergence Change:** -1.5 (Indicates short-term decline)
*   **Expected Return (%):** 3392.4% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI indicates a low-risk environment.
*   The RSI suggests the stock is approaching oversold territory.
*   The negative PPO indicates a bearish trend.
*   The Hybrid Signal recommends selling a small portion of holdings and maintaining a high cash position, indicating caution.
*   The recent negative change in relative divergence confirms a short-term downward trend.
*   The exceptionally high expected return (3392.4%) should be viewed with caution. This is a long-term projection, and the model likely anticipates a significant rebound from the current depressed levels.

**4. Recent News & Significant Events**

*   Several news articles highlight recent positive developments: earnings beat, cost cuts, price target increases, and outperformance relative to the broader market.
*   Zacks Industry Outlook mentions Albemarle alongside DuPont de Nemours and Methanex.
*   However, articles also mention demand worries in the diversified chemical sector.

**Analysis:** Recent news is mixed, with positive catalysts like earnings beats and cost reductions, but concerns about broader industry demand. The analyst activity suggests the stock is being actively monitored.

**4-2) Analyst Opinions:**

*   **Consensus:** Hold
*   **Mean Rating:** 2.64 (~Hold)
*   **Target Price (avg/high/low):** 85.97 / 200.00 / 58.00

**Analysis:** The analyst consensus is a "Hold" with a mean rating reflecting a neutral stance. The average target price of $85.97 suggests a potential upside. However, the wide range between the high and low target prices indicates significant disagreement among analysts.

**5. Recent Earnings Analysis:**

| 날짜       | EPS    | 매출       |
|------------|--------|------------|
| 2025-08-04 | -0.16  | 1.33 B$    |
| 2025-04-30 | 0      | 1.08 B$    |
| 2024-11-06 | -9.45  | 1.35 B$    |
| 2024-07-31 | -1.96  | 1.43 B$    |
| 2025-08-04 | -1.96  | 1.43 B$    |

**Analysis:** Earnings per share (EPS) has been negative for the recent quarters, with a significant loss in Q4 2024. Revenue has fluctuated but generally remains above $1 billion. The recurring data point (2025-08-04) is likely a data entry error.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | $1.33B     | 14.80%        |
| 2025-03-31 | $1.08B     | 14.51%        |
| 2024-12-31 | $1.23B     | 11.22%        |
| 2024-09-30 | $1.35B     | -7.68%        |
| 2024-06-30 | $1.43B     | -0.74%        |

**Capital and Profitability:**

| Quarter    | Equity      | ROE      |
|------------|-------------|----------|
| 2025-06-30 | $10.24B    | 0.22%    |
| 2025-03-31 | $10.03B    | 0.41%    |
| 2024-12-31 | $9.96B     | 0.76%    |
| 2024-09-30 | $10.24B    | -10.44%  |
| 2024-06-30 | $11.22B    | -1.68%   |

**Analysis:** Revenue has fluctuated. Profit margins were negative in the middle of the period, but have rebounded recently. Equity has remained relatively stable around $10 billion, but declined sharply and then recovered. Return on Equity (ROE) was negative, but now positive.

**7. Overall Analysis & Summary**

Albemarle (ALB) presents a mixed picture.

*   **Negative Trends:** Significant underperformance compared to the S&P 500, negative alpha in recent periods, and recent negative earnings.
*   **Positive Signs:** Recent positive news related to earnings beats and cost reductions. The MRI suggests a low-risk market environment. The RSI is approaching oversold territory, which could signal a potential rebound. Profitability seems to be improving.
*   **Concerns:**  High maximum drawdowns indicating significant risk. Analyst consensus is a "Hold" with a wide range of target prices. The extremely high projected long-term return is optimistic and requires further scrutiny. Broader industry demand worries persist.

**Recommendation:** Given the mixed signals, a cautious approach is warranted. Investors should carefully weigh the positive news against the recent underperformance and negative trends. A thorough understanding of the factors driving the expected long-term return is crucial before making any investment decisions. Further investigation into the company's cost-cutting measures, and the outlook for lithium demand are advisable.
